OncoMatch/Clinical Trials/NCT07317505
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Is NCT07317505 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JMT108 for cancer.
Treatment: JMT108 — The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care
Participants...who are unresponsive or intolerant to all standard of care or have no standard of care available
Cannot have received: unapproved investigational drugs or treatments
Any other unapproved investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug (C1D1)
Cannot have received: chemotherapy
Exception: nitrosoureas or mitomycin C within 6 weeks
Chemotherapy...within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 1. Nitrosoureas or mitomycin C within 6 weeks prior to the first dose
Cannot have received: radiotherapy
Radiotherapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: biological therapy
Biological therapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: endocrine therapy
Endocrine therapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: targeted therapy
Exception: oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives (whichever is longer)
Targeted therapy within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 2. Use of oral fluoropyrimidines and small-molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer)
Cannot have received: immunotherapy
Immunotherapy within 4 weeks prior to the first dose of the investigational drug
Cannot have received: other anti-tumor therapies
Exception: herbal medicine/products with anti-tumor indications within 2 weeks
Other anti-tumor therapies within 4 weeks prior to the first dose of the investigational drug, except in the following situations: 3. Use of herbal medicine/products with anti-tumor indications within 2 weeks prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Carolina BioOncology Institute · Huntersville, North Carolina
- NEXT Dallas · Dallas, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify